# Silicon2 and Korea Value-Up Silicon2 is not a Value-Up play. Its catalyst is in operations: margin and inventory. A governance catalyst is not part of the thesis. This difference explains its low conviction. ## Silicon2 in the 13 Nov 2026 Korea shortlist | # | Company | Shortlist label | Catalyst type | "Market corrects" leg | Conviction | |---|---|---|---|---|---| | 1 | Silicon2 | Compounder | operations (Q4 margin, inventory) | 0.44 | 0.31 | | 2 | DoubleUGames | Re-rating | governance (DDI buy-in ends the double listing) | 0.55 | 0.31 | | 3 | PharmaResearch | Compounder, priced for it | operations (Rejuran growth) | not in this note | 0.22 | Source: `Mario Jude Fund/One-Pagers/2026-11-13 Korea shortlist (all three).pdf` ## The lesson from the table - DoubleUGames has a "market corrects" leg of 0.55 because the DDI buy-in is a named event with a date. - Silicon2 has 0.44 because a margin recovery is not sure, and no date is set. - A governance event gives a higher "market corrects" leg than an operations recovery. See [[Value Trap Test for Cheap Stocks]]. - Thus the two Value-Up-type names clear the value-trap flag more easily than the compounders. ## Value-Up levers at Silicon2 | Lever | Status at Silicon2 | Strength | |---|---|---| | Buyback | ₩5bn to Apr 2027, reference price ₩34,200 | weak: about 0.3% of the market cap | | Cancellation of treasury shares | not known | check DART | | Dividend | 1.2% yield | weak | | Value-Up disclosure (plan filed with KRX) | not known | check KRX | | Holding-company or double-listing discount | none | not applicable | | Controlling holder | founder and family, 43.4% | founder sells, does not buy | ## What would make Silicon2 a Value-Up play 1. A larger buyback, with cancellation of the shares. 2. A payout target, for example a fixed share of net income as dividend. 3. A Value-Up plan with a return-on-equity target. 4. The founder stops sales on the market. If one of these occurs, the catalyst gets a date. Then the "market corrects" leg can go above 0.5, and the value-trap flag clears. ## The CVC link - CVC holds RCPS in Silicon2 and in PharmaResearch, two of the three shortlist names. See [[CVC RCPS in Korean Mid-Caps]]. - A private-equity holder with a redemption right can push for capital return. It can also take cash out of the company. > [!warning] Not checked against my own notes > I wrote this from the shortlist. [[Korea Corporate Value-Up Program]] and [[Korea Discount]] are offline in iCloud. Compare this note with them when they download. ---- tags: #boat #investing #korea links: [[Silicon2 MOC]] [[Korea Corporate Value-Up Program]] [[Korea Discount]] [[Silicon2 Investment Thesis]]